{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T05:46:12Z","timestamp":1791179172826,"version":"4.1.0"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T00:00:00Z","timestamp":1416182400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2015,3]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Belinostat is a pan\u2010histone deacetylase inhibitor with antitumour and anti\u2010angiogenic properties. An open label, multicentre study was conducted in patients with peripheral T\u2010cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    ) or cutaneous T\u2010cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>\n                    ) who failed \u22651 prior systemic therapy and were treated with belinostat (1000\u00a0mg\/m\n                    <jats:sup>2<\/jats:sup>\n                    intravenously \u00d75\u00a0d of a 21\u2010d cycle). The primary endpoint was objective response rate (\n                    <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>\n                    ). Patients with\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a024) had received a median of three prior systemic therapies (range 1\u20139) and 40% had stage\n                    <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>\n                    disease. Patients with\n                    <jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>\n                    (\n                    <jats:italic>n<\/jats:italic>\n                    \u00a0=\u00a029) had received a median of one prior skin\u2010directed therapy (range 0\u20134) and four prior systemic therapies (range 1\u20139); 55% had stage\n                    <jats:styled-content style=\"fixed-case\">IV<\/jats:styled-content>\n                    disease. The\n                    <jats:styled-content style=\"fixed-case\">ORR<\/jats:styled-content>\n                    s were 25% (\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    ) and 14% (\n                    <jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>\n                    ). Treatment\u2010related adverse events occurred in 77% of patients; nausea (43%), vomiting (21%), infusion site pain (13%) and dizziness (11%) had the highest incidence. Treatment\u2010related serious adverse events were Grade 5 ventricular fibrillation; Grade 4 thrombocytopenia; Grade 3 peripheral oedema, apraxia, paralytic ileus and pneumonitis; and Grade 2 jugular vein thrombosis. Belinostat monotherapy was well tolerated and efficacious in patients with recurrent\/refractory\n                    <jats:styled-content style=\"fixed-case\">PTCL<\/jats:styled-content>\n                    and\n                    <jats:styled-content style=\"fixed-case\">CTCL<\/jats:styled-content>\n                    . This trial was registered at\n                    <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"http:\/\/www.clinicaltrials.gov\">www.clinicaltrials.gov<\/jats:ext-link>\n                    as\n                    <jats:styled-content style=\"fixed-case\">NCT<\/jats:styled-content>\n                    00274651.\n                  <\/jats:p>","DOI":"10.1111\/bjh.13222","type":"journal-article","created":{"date-parts":[[2014,11,17]],"date-time":"2014-11-17T23:31:20Z","timestamp":1416267080000},"page":"811-819","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":170,"title":["A Phase\n                    <scp>II<\/scp>\n                    trial of Belinostat (\n                    <scp>PXD<\/scp>\n                    101) in patients with relapsed or refractory peripheral or cutaneous T\u2010cell lymphoma"],"prefix":"10.1111","volume":"168","author":[{"given":"Francine","family":"Foss","sequence":"first","affiliation":[{"name":"Yale Cancer Center New Haven CT USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranjana","family":"Advani","sequence":"additional","affiliation":[{"name":"Stanford University Stanford CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madeleine","family":"Duvic","sequence":"additional","affiliation":[{"name":"M.D. Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Hymes","sequence":"additional","affiliation":[{"name":"Cancer Institute New York University New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanin","family":"Intragumtornchai","sequence":"additional","affiliation":[{"name":"Department of Medicine Chulalongkorn Hospital Bangkok Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnuparp","family":"Lekhakula","sequence":"additional","affiliation":[{"name":"Department of Medicine Songlanagarind Hospital Songkhla Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ofer","family":"Shpilberg","sequence":"additional","affiliation":[{"name":"Haematology Rabin Medical Centre Beilinson Hospital Davidoff Cancer Centre and Sackler School of Medicine Tel Aviv University Petach Tikva Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Lerner","sequence":"additional","affiliation":[{"name":"Boston Medical Center Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Belt","sequence":"additional","affiliation":[{"name":"Kansas City Cancer Center Kansas City MO USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Jacobsen","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber Cancer Institute Boston MA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laurent","sequence":"additional","affiliation":[{"name":"Hopital Purpan Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Ben\u2010Yehuda","sequence":"additional","affiliation":[{"name":"Division of Haematology Hadassah\u2010Hebrew University Medical Centre Jerusalem Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot\u2010Barry","sequence":"additional","affiliation":[{"name":"Hopital du Haut\u2010Leveque Universite Bordeaux Pessac France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uwe","family":"Hillen","sequence":"additional","affiliation":[{"name":"Universitatsklinikum Essen Essen Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Poul","family":"Knoblauch","sequence":"additional","affiliation":[{"name":"Topotarget Copenhagen Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gajanan","family":"Bhat","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanta","family":"Chawla","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee F.","family":"Allen","sequence":"additional","affiliation":[{"name":"Spectrum Pharmaceuticals Irvine CA USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad","family":"Pohlman","sequence":"additional","affiliation":[{"name":"Hematologic Oncology and Blood Disorders Cleveland Clinic Taussig Cancer Institute Cleveland OH USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2014,11,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1998.16.8.2780"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-08-2786"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-01-293050"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.2403"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.4223"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.9.2456"},{"key":"e_1_2_8_9_1","first-page":"581","article-title":"Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early\u2010stage cutaneous T\u2010cell lymphoma","volume":"137","author":"Duvic M.","year":"2001","journal-title":"Archives of Dermatology"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01102.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2009.1.523"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20070779"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605726"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008418727472"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11315680-000000000-00000"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2672"},{"key":"e_1_2_8_17_1","unstructured":"National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guildelines\u00ae).Non\u2010Hodgkin's Lymphoma. Version 2.2014. 27 March2014. Available atwww.nccn.org."},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-008-0062-3"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.10.2434"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.24759"},{"key":"e_1_2_8_22_1","first-page":"721","article-title":"Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101","volume":"2","author":"Plumb J.A.","year":"2003","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.2386"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.38.0402"},{"key":"e_1_2_8_25_1","doi-asserted-by":"crossref","first-page":"2086","DOI":"10.1158\/1535-7163.MCT-06-0111","article-title":"Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies","volume":"5","author":"Qian X.","year":"2006","journal-title":"Molecular Cancer Therapeutics"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf033"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-1786"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.138.1.42"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.9066"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3502"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.13222","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.13222","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:33:50Z","timestamp":1696332830000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.13222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,17]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["10.1111\/bjh.13222"],"URL":"https:\/\/doi.org\/10.1111\/bjh.13222","archive":["Portico"],"relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.725240084.793539748","asserted-by":"object"}]},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,17]]},"assertion":[{"value":"2014-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-09-04","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}